These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 9342061)
21. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. Ives NJ; Gazzard BG; Easterbrook PJ J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320 [TBL] [Abstract][Full Text] [Related]
22. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care]. Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655 [TBL] [Abstract][Full Text] [Related]
24. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand. Kitajima T; Kobayashi Y; Chaipah W; Sato H; Chadbunchachai W; Thuennadee R AIDS; 2003 Nov; 17(16):2375-81. PubMed ID: 14571190 [TBL] [Abstract][Full Text] [Related]
25. Survival after diagnosis of AIDS among adults resident in the United Kingdom in the era of multiple therapies. Rogers PA; Sinka KJ; Molesworth AM; Evans BG; Allardice GM Commun Dis Public Health; 2000 Sep; 3(3):188-94. PubMed ID: 11014033 [TBL] [Abstract][Full Text] [Related]
26. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Tantisiriwat W; Tebas P; Clifford DB; Powderly WG; Fichtenbaum CJ Clin Infect Dis; 1999 May; 28(5):1152-4. PubMed ID: 10452651 [TBL] [Abstract][Full Text] [Related]
27. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. Velasco M; Gómez A; Fernández C; Pérez-Cecilia E; Téllez MJ; Roca V; Fernández-Cruz A HIV Med; 2000 Oct; 1(4):246-51. PubMed ID: 11737356 [TBL] [Abstract][Full Text] [Related]
28. Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178 [TBL] [Abstract][Full Text] [Related]
29. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections]. Pozio E Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694 [TBL] [Abstract][Full Text] [Related]
30. The impact of integrating food supplementation, nutritional education and HAART (Highly Active Antiretroviral Therapy) on the nutritional status of patients living with HIV/AIDS in Mozambique: results from the DREAM Programme. Scarcella P; Buonomo E; Zimba I; Doro Altan AM; Germano P; Palombi L; Marazzi MC Ig Sanita Pubbl; 2011; 67(1):41-52. PubMed ID: 21468153 [TBL] [Abstract][Full Text] [Related]
31. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Krentz HB; Auld MC; Gill MJ; CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156 [TBL] [Abstract][Full Text] [Related]
32. [A retrospective cohort study on reduction of AIDS mortality among patients enrolled in national-free antiretroviral treatment programme in two cities in China]. Dou ZH; Zhao Y; He Y; He WS; Ji GP; Xu C; Ma Y; Zhao DC; Yu L; Zhang FJ Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Dec; 43(12):1091-5. PubMed ID: 20193506 [TBL] [Abstract][Full Text] [Related]
33. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527 [TBL] [Abstract][Full Text] [Related]
34. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy. Scott Sutton S; Magagnoli J; Hardin JW Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931 [TBL] [Abstract][Full Text] [Related]
35. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. Garattini L; Tediosi F; Di Cintio E; Yin D; Parazzini F; AIDS Care; 2001 Dec; 13(6):733-41. PubMed ID: 11720643 [TBL] [Abstract][Full Text] [Related]
36. The end of AIDS? Leland J Newsweek; 1996 Dec; 128(23):64-8, 71, 73. PubMed ID: 10162943 [No Abstract] [Full Text] [Related]
37. State implementation of the AIDS drug assistance programs. Buchanan RJ; Smith SR Health Care Financ Rev; 1998; 19(3):39-62. PubMed ID: 10345412 [TBL] [Abstract][Full Text] [Related]
38. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre. Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765 [TBL] [Abstract][Full Text] [Related]
39. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. Tassie JM; Gasnault J; Bentata M; Deloumeaux J; Boué F; Billaud E; Costagliola D AIDS; 1999 Oct; 13(14):1881-7. PubMed ID: 10513646 [TBL] [Abstract][Full Text] [Related]
40. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. Pernerstorfer-Schoen H; Schindler K; Parschalk B; Schindl A; Thoeny-Lampert S; Wunderer K; Elmadfa I; Tschachler E; Jilma B AIDS; 1999 Dec; 13(17):2389-96. PubMed ID: 10597780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]